drugset / Trial / NCT03168997

Memantine Treatment in Alzheimer's Disease Patients

NCT03168997

Phase 4 Unknown 222 enrolled Wei Cuibai
Non-randomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to investigate whether there will be any efficacy difference of Memantine treatment in different cognitive severity AD patients stratified with BPSD

Timeline

Start
2017-07-15
Primary completion
2018-09-30
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg Oral

Indications